Development, Optimization, and Validation of an in vitro Cell-Based Bioassay to Determine the Biological Activity of Teriparatide (PTH1–34)

Abstract

This study aimed to establish an efficient in vitro cell-based assay to measure the activity of teriparatide (PTH1–34). In this study, a rat osteosarcoma cell line (UMR-106) was treated with various concentrations of PTH1–34, and the biological activity of PTH1–34 was determined by quantitatively measuring intracellular cyclic adenosine monophosphate levels using a time-resolved fluoroimmunoassay. A four-parameter fitting analysis was used to calculate the relative potency of the samples. The experimental conditions were optimized. The method's specificity, relative accuracy, precision, and linearity were validated. Our data suggested that this method had good specificity, a relative bias of relative accuracy ranging from −0.8 to 1.4%, a correlation coefficient for the linear regression equation of 0.9953, a geometric coefficient of variation for intermediate precision ranges from 2.0 to 3.5%, and a linear range of 50 to 150%. This method significantly improves the quality control and release inspection efficiency of PTH1–34 and may be further developed and validated as an alternative to the existing United States Pharmacopeia and European Pharmacopoeia inclusion methods. This method also provides a platform for the high-throughput screening of PTH1–34 analogs.

Keywords

teriparatide - in vitro bioassay - cAMP - time-resolved fluoroimmunoassay - method verification

Publikationsverlauf

Eingereicht: 09. Januar 2024

Angenommen: 15. Juli 2024

Artikel online veröffentlicht:
06. August 2024

• References

• 1 Jiang X, Xu C, Shi H, Cheng Q. PTH1-34 improves bone healing by promoting angiogenesis and facilitating MSCs migration and differentiation in a stabilized fracture mouse model. PLoS One 2019; 14 (12) e0226163
• 2 Hämmerle SP, Mindeholm L, Launonen A. et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone 2012; 50 (04) 965-973
• 3 Charest-Morin X, Fortin JP, Bawolak MT, Lodge R, Marceau F. Green fluorescent protein fused to peptide agonists of two dissimilar G protein-coupled receptors: novel ligands of the bradykinin B2 (rhodopsin family) receptor and parathyroid hormone PTH1 (secretin family) receptor. Pharmacol Res Perspect 2013; 1 (01) e00004
• 4 Clark LJ, Krieger J, White AD. et al. Allosteric interactions in the parathyroid hormone GPCR-arrestin complex formation. Nat Chem Biol 2020; 16 (10) 1096-1104
• 5 Hoare SR. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 2005; 10 (06) 417-427
• 6 Vasudevan NT. cAMP assays in GPCR drug discovery. Methods Cell Biol 2017; 142: 51-57
• 7 Degan P, Podestà A, Montagnoli G. Time-resolved fluoroimmunoassay. Mol Biotechnol 1999; 13 (03) 215-222
• 8 Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs 2008; 68 (18) 2709-2737
• 9 Bhattacharyya S, Pal S, Chattopadhyay N. Abaloparatide, the second generation osteoanabolic drug: molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol 2019; 166: 185-191
• 10 Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ. PTH receptor-1 signalling-mechanistic insights and therapeutic prospects. Nat Rev Endocrinol 2015; 11 (12) 712-724
• 11 International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS. Fed Regist 1999; 64 (159) 44928-44935
• 12 The United States Pharmacopeial Convention. The United States Pharmacopeia: General Chapters, 43th ed. Rockville: The United States Pharmacopeial Convention; 2021: 4275
• 13 Liu AM, New DC, Lo RK, Wong YH. Reporter gene assays. Methods Mol Biol 2009; 486: 109-123
• 14 Wang L, Yu C, Wang J. Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnol Adv 2020; 39: 107466